|Application ||WB, E|
|Other Accession||Q9WUE4, NP_006536.3|
|Calculated MW||43658 Da|
|Antigen Region||346-373 aa|
|Other Names||Nitrogen permease regulator 2-like protein, NPR2-like protein, Gene 21 protein, G21 protein, Tumor suppressor candidate 4, NPRL2, TUSC4|
|Target/Specificity||This NPRL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 346-373 amino acids from the C-terminal region of human NPRL2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||NPRL2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Suppresses Src-dependent tyrosine phosphorylation and activation of PDPK1 and its downstream signaling. Down-regulates PDPK1 kinase activity by interfering with tyrosine phosphorylation at 'Tyr-9', 'Tyr-373' and 'Tyr-376' residues. May act as a tumor suppressor. Suppresses cell growth and enhances sensitivity to various anticancer drugs.|
|Tissue Location||Most abundant in skeletal muscle, followed by brain, liver and pancreas, with lower amounts in lung, kidney, placenta and heart. Expressed in the frontal lobe cortex as well as in the temporal, parietal, and occipital lobes (PubMed:27173016, PubMed:26505888). Expressed in most lung cancer cell lines tested.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Suppresses Src-dependent tyrosine phosphorylation and activation of PDPK1 and its downstream signaling. Down-regulates PDPK1 kinase activity by interfering with tyrosine phosphorylation at the Tyr-9 Tyr-373 and Tyr-376 residues. May act as a tumor suppressor. Suppresses cell growth and enhanced sensitivity to various anticancer drugs.
Spielewoy, N., et al. Eukaryotic Cell 9(4):592-601(2010)
Otani, S., et al. J Surg Oncol 100(5):358-363(2009)
Neklesa, T.K., et al. PLoS Genet. 5 (6), E1000515 (2009) :
Anedchenko, E.A., et al. Mol. Biol. (Mosk.) 42(6):965-976(2008)
Kurata, A., et al. Cancer Sci. 99(9):1827-1834(2008)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.